Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its paliperidone palmitate injection. This second-generation antipsychotic long-acting injection is now approved for the treatment of schizophrenia during both the acute and maintenance phases.
The monthly medication, featuring paliperidone as the active ingredient, is recognized as a first-line therapy for schizophrenia. It effectively addresses positive symptoms, negative symptoms, emotional symptoms, and cognitive functions associated with the disorder. The long-acting injection offers a significant advantage over oral formulations by requiring less frequent administration while maintaining a stable therapeutic drug level over an extended period. This attribute is expected to enhance patient compliance and substantially reduce the risk of relapse in individuals with schizophrenia.- Flcube.com
